TG4050 is an individualized therapeutic vaccine
A particularly innovative immunotherapy, TG4050 is the lead myvac ® candidate.
First positive data
from Phase I clinical trials
Initial data presented at the ASCO congress (June 2022)
One cancer, one patient, one vaccine
With TG4050, Transgene is developing an individualized immunotherapy based on advanced genetic engineering and artificial intelligence (AI) technologies.
The treatment is based on an optimized MVA viral vector.
Each treatment is designed and manufactured by Transgene for each patient, targeting the most relevant tumor targets (cancer-specific neoantigens) selected by NEC’s AI.
Once injected into the patient, this therapeutic vaccine will stimulate the patient’s immune defenses to allow the targeted destruction of cancer cells.
To carry out this project, Transgene relies on a unique expertise, a network of prestigious and recognized partners at every stage of product development and integrated manufacturing capabilities.
Transgene has signed a strategic collaboration agreement with NEC for the development of TG4050, the first candidate derived from the myvac® platform. This personalized immunotherapy is developed for each patient, on the basis of mutations identified through sequencing of tumor tissue, prioritized using NEC’s Neoantigen Prediction System and delivered using Transgene’s myvac® technological platform which allows development and manufacturing.
- September 27, 2022 - R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
- June 6, 2022 - Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
- May 27, 2022 - Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
- Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)
- Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
- Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
B. Mallone et al.
Download the poster here